Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome

  1. Mengyuan Ge
  2. Judith Molina
  3. Jin Ju Kim
  4. Shamroop Kumar Mallela
  5. Anis Ahmad
  6. Javier Varona Santos
  7. Hassan Al-Ali
  8. Alla Mitrofanova
  9. Kumar Sharma
  10. Flavia Fontanesi
  11. Sandra Merscher
  12. Alessia Fornoni  Is a corresponding author
  1. University of Miami, United States
  2. The University of Texas Health Science Center at San Antonio, United States

Peer review process

This article was accepted for publication via eLife's original publishing model. eLife publishes the authors' accepted manuscript as a PDF only version before the full Version of Record is ready for publication. Peer reviews are published along with the Version of Record.

History

  1. Version of Record published
  2. Accepted Manuscript published
  3. Accepted
  4. Preprint posted
  5. Received

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Mengyuan Ge
  2. Judith Molina
  3. Jin Ju Kim
  4. Shamroop Kumar Mallela
  5. Anis Ahmad
  6. Javier Varona Santos
  7. Hassan Al-Ali
  8. Alla Mitrofanova
  9. Kumar Sharma
  10. Flavia Fontanesi
  11. Sandra Merscher
  12. Alessia Fornoni
(2023)
Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome
eLife 12:e83353.
https://doi.org/10.7554/eLife.83353

Share this article

https://doi.org/10.7554/eLife.83353